Deals Of The Week: Shire/Heptares, NicOx/Altacor, UCB/Oxford University
Executive Summary
This past week saw two GPCR-focused deals – Shire’s optioning of a preclinical adenosine A2a antagonist and Anaphore’s acquisition of a platform company specializing in biologics targeting GPCRs.
You may also be interested in...
Deals Of The Week Wonders: What Does Merck’s Latest Biosimilar Move Really Mean?
Plus a look at Roche/Chiasma, Chiesi/Cornerstone, Eisai/Valeant and more
China First: RuiYi Takes Exclusive License To arGEN-X’s Anti-IL6 Antibody
The China/U.S.-based company RuiYi is to develop an anti-IL6 antibody licensed from Belgium’s arGEN-X first in China.
China First: RuiYi Takes Exclusive License To arGEN-X’s Anti-IL6 Antibody
The China/U.S.-based company RuiYi is to develop an anti-IL6 antibody licensed from Belgium’s arGEN-X first in China.